Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -0.20% is 1433% below its 5-year average of 0.01%, near the high end of its 5-year range (-14.34%–4.64%).
97.24% above its 12-month average of -7.25%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 0.12%.
RETURN ON ASSETS (ROA)
-0.20%
RETURN ON ASSETS (ROA) AVG TTM
-7.25%
RETURN ON ASSETS (ROA) AVG 3Y
-2.02%
RETURN ON ASSETS (ROA) AVG 5Y
0.01%
RETURN ON ASSETS (ROA) AVG 10Y
0.86%
RETURN ON ASSETS (ROA) AVG 15Y
2.47%
RETURN ON ASSETS (ROA) AVG 20Y
3.15%
CURRENT VS TTM AVG
+97.24%
CURRENT VS 3Y AVG
+90.10%
CURRENT VS 5Y AVG
-1433.33%
CURRENT VS 10Y AVG
-123.13%
CURRENT VS 15Y AVG
-108.10%
CURRENT VS 20Y AVG
-106.35%
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
+99.36%
vs the sector median at left
Integra LifeSciences Holdings Corporation
Market Cap
$1.04B
Return on Assets (ROA)
-0.20%
TTM Avg
-7.25%
3Y Avg
-2.02%
5Y Avg
0.01%
Market Cap
$1.03B
Return on Assets (ROA)
-43.17%
TTM Avg
-16.38%
3Y Avg
-11.13%
5Y Avg
-30.16%
Market Cap
$1.03B
Return on Assets (ROA)
-10.18%
TTM Avg
-8.89%
3Y Avg
-12.61%
5Y Avg
-16.81%
Market Cap
$1.04B
Return on Assets (ROA)
-56.27%
TTM Avg
-37.98%
3Y Avg
-21.94%
5Y Avg
-21.15%
Market Cap
$1.03B
Return on Assets (ROA)
-3.46%
TTM Avg
-0.37%
3Y Avg
-7.11%
5Y Avg
-6.26%
Market Cap
$1.05B
Return on Assets (ROA)
-6.43%
TTM Avg
-17.46%
3Y Avg
-82.63%
5Y Avg
-55.94%
Market Cap
$1.02B
Return on Assets (ROA)
-1.53%
TTM Avg
-4.15%
3Y Avg
-5.20%
5Y Avg
-5.20%
Market Cap
$1.00B
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.08B
Return on Assets (ROA)
20.05%
TTM Avg
20.12%
3Y Avg
18.47%
5Y Avg
14.51%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Integra LifeSciences Holdings Corporation (IART) | $1.04B | -0.20% | -7.25% | -2.02% | 0.01% |
| Immatics N.V. (IMTX)vs › | $1.03B | -43.17% | -16.38% | -11.13% | -30.16% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.03B | -10.18% | -8.89% | -12.61% | -16.81% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.04B | -56.27% | -37.98% | -21.94% | -21.15% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.03B | -3.46% | -0.37% | -7.11% | -6.26% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -6.43% | -17.46% | -82.63% | -55.94% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | -1.53% | -4.15% | -5.20% | -5.20% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.00B | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 20.05% | 20.12% | 18.47% | 14.51% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.20M | -22.90% | -17.96% | -22.57% | -25.02% |
ROA
-0.2%
ROE
-0.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -14.34% |
| 2024-12-31 | -0.17% |
| 2023-12-31 | 1.79% |
| 2022-12-31 | 4.64% |
| 2021-12-31 | 4.47% |
| 2020-12-31 | 3.70% |
| 2019-12-31 | 1.52% |
| 2018-12-31 | 1.96% |
| 2017-12-31 | 2.02% |
| 2016-12-31 | 4.12% |
| 2015-12-31 | -0.20% |
| 2014-12-31 | 2.15% |
| 2013-12-31 | -1.42% |
| 2012-12-31 | 3.54% |
| 2011-12-31 | 2.45% |
| 2010-12-31 | 6.46% |
| 2009-12-31 | 5.42% |
| 2008-12-31 | 3.38% |
| 2007-12-31 | 4.09% |
| 2006-12-31 | 4.79% |
| 2005-12-31 | 8.29% |
| 2004-12-31 | 3.77% |
| 2003-12-31 | 6.51% |
| 2002-12-31 | 12.84% |
| 2001-12-31 | 11.50% |
| 2000-12-31 | -13.21% |
| 1999-12-31 | -9.05% |
| 1998-12-31 | -35.45% |
| 1997-12-31 | -44.27% |
| 1996-12-31 | -15.40% |
